AbbVie’s Dividend Growth Faces Pfizer’s 6.2% Yield

AbbVie’s quarterly dividend is $1.73 per share, while Pfizer pays $0.43. At recent share prices, those payouts translate to yields of roughly 2.6% for AbbVie and 6.2% for Pfizer, according to the September comparison.

Pfizer offers more cash income today. But the gap also reflects investors’ different expectations for the drugmakers’ businesses. Yields change with share prices, and a high yield alone does not show whether a payout is secure.

AbbVie’s latest results showed stronger sales momentum. The company reported $16.99 billion in second-quarter revenue, up 10.2% year over year. Its immunology drugs Skyrizi and Rinvoq brought in a combined $8.03 billion, with sales of each rising about 24%.

Those medicines are helping AbbVie offset Humira’s decline after U.S. patent protection ended. Humira revenue fell 35.9% in the quarter to $756 million. The shift shows progress, but the company still needs its newer drugs to keep growing as older products face competition.

Pfizer’s second-quarter revenue was $15.03 billion, up 1% operationally, a measure that excludes currency effects. Sales of launched and acquired products rose 18% operationally, but revenue excluding its COVID-19 products grew 5%. The company reported an adjusted profit of 77 cents per share and a GAAP loss of 4 cents, including $4.3 billion in non-cash asset impairments.

Pfizer raised the midpoint of its 2026 revenue outlook by $500 million, to a range of $60.5 billion to $62.5 billion. It kept its adjusted earnings forecast at $2.80 to $3.00 per share. The figures point to improving product sales, but the company still has to replace declining COVID-related revenue and manage upcoming patent expirations.

For investors seeking current income, Pfizer’s larger payout stands out. AbbVie may better suit investors prioritizing growing sales and a rising dividend. The key test for both is whether new medicines can keep producing enough cash to support their payouts.